Ongoing clinical trials in further lines of treatment for SCLC
| Clinical trial ID | Phase | Setting | Regimen | Endpoint |
|---|---|---|---|---|
| NCT02963090 | II | 2nd line | Pembrolizumab vs topotecan | PFS |
| NCT03059667 | II | 2nd line | Atezolizumab vs standard chemotherapy | RR (non-comparative) |
| NCT02331251 (PembroPlus) | Ib/II | ≥ 2nd line (solid tumors) | Pembrolizumab plus irinotecan | RP2D |
| NCT03253068 | II | 2nd line | Pembrolizumab plus Amrubicin | ORR |
| NCT02551432 | II | ≥ 2nd line | Pembrolizumab plus Paclitaxel | RR |
| NCT03262454 | II | 2nd line | Atezolizumab + RT | RR |
| NCT03026166 | I/II | ≥ 2nd line | Rova-T plus Nivolumab +/− ipilimumab | DLT |
| NCT03083691 (BIOLUMA) | II | 2nd line | Nivolumab plus ipilimumab | ORR |
| NCT02701400 | II | 2nd -3rd line | Tremelimumab plus Durvalumab +/− RT | PFSORR |
| NCT02554812 | Ib/II | ≥ 2nd line | Avelumab plus utomilumab | DLTOR |
OS Overall Survival, PFS Progression Free Survival, RR Response Rate, RP2D Recommended phase 2 dose, Rova-T Rovalpituzumab Tesirine, ORR Overall Response Rate, MTD Maximum Tolerated Dose, DLT Dose limiting toxicities